Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00EQL
|
||||
| Former ID |
DIB016694
|
||||
| Drug Name |
EPZ-6438
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Epizyme
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C34H44N4O4
|
||||
| InChI |
InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)
|
||||
| InChIKey |
NSQSAUGJQHDYNO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Enhancer of zeste homolog 2 | Target Info | Inhibitor | [532681] | |
| KEGG Pathway | MicroRNAs in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | ||||
| Endoderm Differentiation | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Histone Modifications | |||||
| Cell Differentiation - meta | |||||
| miRs in Muscle Cell Differentiation | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| References | |||||
| Ref 532681 | Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014 Apr;13(4):842-54. | ||||
| Ref 542041 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7011). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.